Literature DB >> 14734196

Urinary markers of bladder carcinoma.

Pranab Dey1.   

Abstract

PURPOSE: Transitional cell carcinoma of bladder is one of the most common tumors of genitourinary tract. Cystoscopy along with cytology is the mainstay for diagnosing bladder cancer. Cytology is specific for diagnosis of bladder carcinomas but less sensitive particularly in low-grade disease. Cystoscopy on the other hand is invasive and relatively costly technique and may also be inconclusive at times particularly in case of cystitis. A simple noninvasive marker for detecting bladder cancer would be helpful. A clinically useful urinary marker should be easy to perform, should have minimum requirements for sample preparations and should have high sensitivity and specificity in diagnosis. In this review we discussed the various urinary markers and their role in detection of bladder cancer.
MATERIALS AND METHODS: We reviewed the literature on urinary markers and tests that may have clinical usefulness.
RESULTS: Several urinary markers and tests such as BTA Stat, BTA TRAK, NMP22, telomerase, HA and HAse tests, Immunocyt, Quanticyt, FDP, BLCA-4, FISH, CYFRA-21-1 have enough potential for future clinical use. BTA stat, NMP22 (bladder check)and AccuDX (FDP) tests are presently point of care tests. The rest of the tests are laboratory-based and may need trained technicians. Majorities of the urinary markers have higher sensitivity and specificity than cytology. However, voided urinary cytology has the highest specificity.
CONCLUSIONS: Till now there is no urinary marker or test that can replace the need of cystoscopy. However, some markers have the potential for future clinical use.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14734196     DOI: 10.1016/j.cccn.2003.11.008

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  12 in total

1.  Diagnostic value of fibronectin and mutant p53 in the urine of patients with bladder cancer: impact on clinicopathological features and disease recurrence.

Authors:  Sanaa Eissa; Samir F Zohny; Abdel-Rahman N Zekri; Tarek Mostafa El-Zayat; Amany M Maher
Journal:  Med Oncol       Date:  2009-12-11       Impact factor: 3.064

2.  Prognostic value of urinary cytology and other biomarkers for recurrence and progression in bladder cancer: a prospective study.

Authors:  Michael D Bell; Faysal A Yafi; Fadi Brimo; Jordan Steinberg; Armen G Aprikian; Simon Tanguay; Wassim Kassouf
Journal:  World J Urol       Date:  2016-02-23       Impact factor: 4.226

3.  [Urine cytology and urine markers. Significance for clinical practice].

Authors:  S Tritschler; D Zaak; R Knuechel; C G Stief
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

Review 4.  Diagnostic accuracy of cytokeratin-19 fragment (CYFRA 21-1) for bladder cancer: a systematic review and meta-analysis.

Authors:  Yuan-Lan Huang; Jie Chen; Wei Yan; Ding Zang; Qin Qin; An-Mei Deng
Journal:  Tumour Biol       Date:  2015-04-09

5.  Rapid diagnosis and follow up of bladder cancer patients using urinary high molecular weight cytokeratins.

Authors:  Abdelfattah M Attallah; Hanem A Sakr; Hisham Ismail; Mohamed F Ismail; Ashraf S Ibrahim; Mohamed M El-Sharabasy; Ibrahim El-Dosoky
Journal:  World J Urol       Date:  2006-05-17       Impact factor: 4.226

6.  Anti-tumour efficacy of mitofusin-2 in urinary bladder carcinoma.

Authors:  Baiye Jin; Guanghou Fu; Hao Pan; Xiaofei Cheng; Lin Zhou; Jia Lv; Geming Chen; Shusen Zheng
Journal:  Med Oncol       Date:  2010-08-28       Impact factor: 3.064

7.  UHRF1 is a novel molecular marker for diagnosis and the prognosis of bladder cancer.

Authors:  M Unoki; J D Kelly; D E Neal; B A J Ponder; Y Nakamura; R Hamamoto
Journal:  Br J Cancer       Date:  2009-06-02       Impact factor: 7.640

8.  Biomarkers for detection and surveillance of bladder cancer.

Authors:  Lorne I Budman; Wassim Kassouf; Jordan R Steinberg
Journal:  Can Urol Assoc J       Date:  2008-06       Impact factor: 1.862

9.  Long interspersed nuclear element-1 hypomethylation and oxidative stress: correlation and bladder cancer diagnostic potential.

Authors:  Maturada Patchsung; Chanchai Boonla; Passakorn Amnattrakul; Thasinas Dissayabutra; Apiwat Mutirangura; Piyaratana Tosukhowong
Journal:  PLoS One       Date:  2012-05-15       Impact factor: 3.240

10.  Inhibition of Lon blocks cell proliferation, enhances chemosensitivity by promoting apoptosis and decreases cellular bioenergetics of bladder cancer: potential roles of Lon as a prognostic marker and therapeutic target in baldder cancer.

Authors:  Yongzhang Liu; Linhua Lan; Kate Huang; Rongrong Wang; Cuicui Xu; Yang Shi; Xiaoyi Wu; Zhi Wu; Jiliang Zhang; Lin Chen; Lu Wang; Xiaomin Yu; Haibo Zhu; Bin Lu
Journal:  Oncotarget       Date:  2014-11-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.